ArticleBMC gastroenterology2025
Portal vein thrombosis and Esophageal-Gastric variceal bleeding in cirrhosis: shared risk factors and causal relationship.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A linear clinical prediction model and nomogram evaluating risk of portal vein thrombosis in liver cirrhosis.BMC gastroenterology · 2026Article
- Hemostasis in Liver Disease Within Patient Blood Management: A Scoping Review of the Current Literature.Journal of clinical medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveThis study aims to investigate the shared risk factors and the causal relationship between esophageal varices bleeding (EGVB) and portal vein thrombosis (PVT) in cirrhotic patients.
methodsA retrospective analysis was conducted on data from 1,223 patients diagnosed with cirrhosis at the First Hospital of Quanzhou from January 1, 2014, to December 31, 2023. After screening, 247 patients were included in a 10-year follow-up study. Differential analysis, univariate and multivariate logistic regression analyses were performed to identify independent risk factors for both PVT and EGVB. The inverse probability of treatment weighting (IPTW) method was used to adjust for potential confounders and assess the impact of PVT on the incidence of EGVB.
resultsIncreased portal vein diameter and reduced hemoglobin levels were identified as independent risk factors for both PVT and EGVB. The incidence of EGVB was higher than that of PVT, with a median time to occurrence of 2 months for EGVB and 16.93 months for PVT. Among patients who developed both complications, PVT occurred before EGVB in 61.43% of cases. IPTW analysis revealed that the incidence of EGVB was significantly higher in the PVT group compared to the non-PVT group (P = 0.043), indicating that PVT significantly increases the risk of EGVB.
conclusionStrategies to reduce portal vein pressure and improve anemia may help prevent both PVT and EGVB. Effective management of PVT is essential to reduce the incidence of EGVB in cirrhotic patients. Future research should involve larger sample sizes to further validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.